On 11 March 2021, the Danish Health Authority suspended the use of the AstraZeneca COVID-19 vaccine (Vaxzevria®) pending national and international investigations into safety signals. “In the following four weeks, a new syndrome was described (Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT), causality was established and a Danish-Norwegian registry study that the estimated the excess of VITT following Vaxzevria® as 1 per 40.000 vaccinated. Based on these findings, and a contextual assessment of the current Danish epidemic, on 14 April 2021 the Danish Health Authority decided to continue vaccine roll-out in Denmark without Vaxzevria® within the national COVID-19 vaccine program.
The aim of this webinar is to share insights and considerations in a transparent manner. Thus, the webinar will present the latest information on the epidemiology, possible pathophysiology, diagnosis, treatment and public health implications of VITT.
Each session consists of comprehensive presentations followed by discussion, which is moderated by experts.
ProgrammeDuring the 3-hour virtual webinar, comprehensive presentations will be followed by discussions, which will be moderated by the respective experts.
Information about the speaker can be found on the streaming site.
Registration is required, but the webinar is open to all, free of charge.
How to join the live broadcast.On entering the site, you will be first prompted to accept the Terms & Conditions of use.
You will be asked to enter your email address, and once submitted, you will immediately receive an email with an activation code. Enter the activation code and your name and you will enter the live platform.